Overexpression of membrane proteins in primary and metastatic gastrointestinal neuroendocrine tumors

Annals of Surgical Oncology

Volumn 20, Issue 3 SUPPL., 2013, Pages

  Carr, Jennifer C ^a   Sherman, Scott K ^a   Wang, Donghong ^a   Dahdaleh, Fadi S ^a   Bellizzi, Andrew M ^a   O'Dorisio, M Sue ^a   O'Dorisio, Thomas M ^a   Howe, James R ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A1 RECEPTOR; CHEMOKINE RECEPTOR CX3CR1; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MEMBRANE PROTEIN; MEPRIN; MEPRIN A BETA RECEPTOR PROTEIN; MESSENGER RNA; MUCIN; MUCIN 13 PROTEIN; OXYTOCIN RECEPTOR; RNA POLYMERASE II; SECRETIN RECEPTOR PROTEIN; UNCLASSIFIED DRUG; METALLOPROTEINASE; MUC13 PROTEIN, HUMAN; OXTR PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LYMPH NODE METASTASIS; NEUROENDOCRINE TUMOR; PANCREATIC NEUROENDOCRINE TUMOR; POLYMERASE CHAIN REACTION; PRIMARY TUMOR; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SMALL BOWEL NEUROENDOCRINE TUMOR; SMALL INTESTINE TUMOR; CANCER STAGING; COMPARATIVE STUDY; ENZYME IMMUNOASSAY; GASTROINTESTINAL TUMOR; GENETICS; LIVER TUMOR; METABOLISM; PANCREAS TUMOR; PATHOLOGY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SECONDARY; SMALL INTESTINE;

GASTROINTESTINAL NEOPLASMS; HUMANS; IMMUNOENZYME TECHNIQUES; INTESTINE, SMALL; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MEMBRANE PROTEINS; METALLOENDOPEPTIDASES; MUCINS; NEOPLASM STAGING; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, OXYTOCIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 84887883971     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-013-3318-6     Document Type: Article

References (36)

1. Yao JC, Hassan M, Phan A, et al. One hundred years after ''carcinoid'': epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063-72.
2. Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9:61-72.
3. Rinke A, Muller HH, Schade-Brittinger C, et al. Placebocontrolled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009; 27:4656-63.
4. Oberg K, Knigge U, Kwekkeboom D, Perren A. Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23 Suppl 7:vii124-30.
5. Kvols LK, Oberg KE, O'Dorisio TM, et al. Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. Endocr Relat Cancer. 2012;19:657-66.
6. Sideris L, Dube P, Rinke A. Antitumor effects of somatostatin analogs in neuroendocrine tumors. Oncologist. 2012;17:747-55.
7. Hofland LJ, Lamberts SW. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev. 2003;24:28-47.
8. Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123ITyr3]- octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20:716-31.
9. Gabriel M, Decristoforo C, Kendler D, et al. 68 Ga-DOTA-Tyr3- octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48:508-18.
10. Zaknun JJ, Bodei L, Mueller-Brand J, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40:800-16.
11. Dahdaleh FS, Lorenzen A, Rajput M, et al. The value of preoperative imaging in small bowel neuroendocrine tumors. Ann Surg Oncol. 2013;20:1912-7.
12. Carr JC, Boese EA, Spanheimer PM, et al. Differentiation of small bowel and pancreatic neuroendocrine tumors by geneexpression profiling. Surgery. 2012;152:998-1007.
13. Buckhaults P, Zhang Z, Chen YC, et al. Identifying tumor origin using a gene expression-based classification map. Cancer Res. 2003;63:4144-9.
14. Wang SC, Parekh JR, Zuraek MB, et al. Identification of unknown primary tumors in patients with neuroendocrine liver metastases. Arch Surg. 2010;145:276-80.
15. Manning M, Misicka A, Olma A, et al. Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics. J Neuroendocrinol. 2012;24:609-28.
16. Ebstein RP, Knafo A, Mankuta D, Chew SH, Lai PS. The contributions of oxytocin and vasopressin pathway genes to human behavior. Horm Behav. 2012;61:359-79.
17. Chini B, Chinol M, Cassoni P, et al. Improved radiotracing of oxytocin receptor-expressing tumours using the new [111In]-DOTALys8- deamino-vasotocin analogue. Br J Cancer. 2003;89:930-6.
18. Klein BY, Tamir H, Welch MG. PI3K/Akt responses to oxytocin stimulation in Caco2BB gut cells. J Cell Biochem. 2011; 112:3216-26.
19. Zhong M, Boseman ML, Millena AC, Khan SA. Oxytocin induces the migration of prostate cancer cells: involvement of the Gi-coupled signaling pathway. Mol Cancer Res. 2010;8:1164-72.
20. Pequeux C, Breton C, Hendrick JC, et al. Oxytocin synthesis and oxytocin receptor expression by cell lines of human small cell carcinoma of the lung stimulate tumor growth through autocrine/ paracrine signaling. Cancer Res. 2002;62:4623-9.
21. Cassoni P, Marrocco T, Bussolati B, et al. Oxytocin induces proliferation and migration in immortalized human dermal microvascular endothelial cells and human breast tumor-derived endothelial cells. Mol Cancer Res. 2006;4:351-9.
22. Cassoni P, Sapino A, Stella A, Fortunati N, Bussolati G. Presence and significance of oxytocin receptors in human neuroblastomas and glial tumors. Int J Cancer. 1998;77:695-700.
23. Cassoni P, Sapino A, Marrocco T, Chini B, Bussolati G. Oxytocin and oxytocin receptors in cancer cells and proliferation. J Neuroendocrinol. 2004;16:362-4.
24. Gravati M, Busnelli M, Bulgheroni E, et al. Dual modulation of inward rectifier potassium currents in olfactory neuronal cells by promiscuous G protein coupling of the oxytocin receptor. J Neurochem. 2010;114:1424-35.
25. Klein BY, Tamir H, Hirschberg DL, Glickstein SB, Welch MG. Oxytocin modulates mTORC1 pathway in the gut. Biochem Biophys Res Commun. 2013;432:466-71.
26. Pitt SC, Chen H, Kunnimalaiyaan M. Phosphatidylinositol 3-kinase-Akt signaling in pulmonary carcinoid cells. J Am Coll Surg. 2009;209:82-8.
27. Oberg KE, Casanovas O, Castano JP, et al. Molecular pathogenesis of neuroendocrine tumors: implications for current and future therapeutic approaches. Clin Cancer Res. 2013;19:2842-9.
28. Pavel ME, Hainsworth JD, Baudin E, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 2011;378:2005-12.
29. Welch MG, Tamir H, Gross KJ, Chen J, Anwar M, Gershon MD. Expression and developmental regulation of oxytocin (OT) and oxytocin receptors (OTR) in the enteric nervous system (ENS) and intestinal epithelium. J Comp Neurol. 2009;512:256-70.
30. Vogel C, Marcotte EM. Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat Rev Genet. 2012;13:227-32.
31. Roth RB, Hevezi P, Lee J, et al. Gene expression analyses reveal molecular relationships among 20 regions of the human CNS. Neurogenetics. 2006;7:67-80.
32. Slaby O, Sachlova M, Bednarikova M, et al. Gene expression of somatostatin receptor 4 predicts clinical outcome of patients with metastatic neuroendocrine tumors treated with somatostatin analogs. Cancer Biother Radiopharm. 2010;25:237-43.
33. Nakayama Y, Wada R, Yajima N, Hakamada K, Yagihashi S. Profiling of somatostatin receptor subtype expression by quantitative PCR and correlation with clinicopathological features in pancreatic endocrine tumors. Pancreas. 2010;39: 1147-54.
34. O'Toole D, Saveanu A, Couvelard A, et al. The analysis of quantitative expression of somatostatin and dopamine receptors in gastro-entero-pancreatic tumours opens new therapeutic strategies. Eur J Endocrinol. 2006;155:849-57.
35. Posorski N, Kaemmerer D, Ernst G, et al. Localization of sporadic neuroendocrine tumors by gene expression analysis of their metastases. Clin Exp Metastasis. 2011;28:637-47.
36. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science. 2013;339:1546-58.